BCAX (Bicara Therapeutics) Beginning Cash Position: $96.69 Mil (As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $29.00
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Beginning Cash Position?

Bicara Therapeutics BCAX +0.31% 12 Beginning Cash Position is $96.69 Mil as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Bicara Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $96.69 Mil.

Bicara Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($200.49 Mil) to Dec. 2025 ($89.34 Mil) but then increased from Dec. 2025 ($89.34 Mil) to Mar. 2026 ($96.69 Mil).

Bicara Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($4.16 Mil) to Dec. 2024 ($230.44 Mil) and increased from Dec. 2024 ($230.44 Mil) to Dec. 2025 ($489.71 Mil).

Bicara Therapeutics Beginning Cash Position Related Terms

Bicara Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Beginning Cash Position Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
4.73 4.16 230.44 489.71

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 489.71 462.07 200.49 89.34 96.69
BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $96.69 Mil mean?
Bicara Therapeutics (BCAX) has a Beginning Cash Position of $96.69 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Beginning Cash Position too high?
Bicara Therapeutics' current Beginning Cash Position is $96.69 Mil. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Beginning Cash Position compare to ZYME and SRPT?
Bicara Therapeutics' Beginning Cash Position of $96.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Beginning Cash Position is $96.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Beginning Cash Position of $96.69 Mil. The current Beginning Cash Position is $96.69 Mil. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Beginning Cash Position is $96.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price